Intermediate uveitis

Intermediate Uveitis Drugs Pipeline Landscape Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 9, 2021
Health, Pharmaceutical

The "Intermediate Uveitis (Ophthalmology) - Drugs in Development, 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Intermediate Uveitis (Ophthalmology) - Drugs in Development, 2021" report has been added to ResearchAndMarkets.com's offering.
  • Additionally, the report provides an overview of key players involved in therapeutic development for Intermediate Uveitis and features dormant and discontinued projects.
  • The report reviews pipeline therapeutics for Intermediate Uveitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The report assesses Intermediate Uveitis (Ophthalmology) therapeutics based on Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.

Global Uveitis Epidemiology and Patient Flow Report 2020-2035: Focus on US, Germany, France, Italy, Spain, UK, Japan, & G7 Countries - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 6, 2021
Health, General Health, Medical specialties, Clinical medicine, Uveitis, Medicine, Intermediate uveitis

b'The "Global Uveitis Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Uveitis Epidemiology and Patient Flow Analysis - 2021, provides Uveitis epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Uveitis Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Uveitis Epidemiology and Patient Flow Analysis - 2021, provides Uveitis epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Uveitis patients, history of the disease at the population level (Uveitis prevalence, Uveitis incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nDemographics: Uveitis patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Uveitis market sizing, assessing market potential, and developing drug forecast models\nIdentify Uveitis patients segments through age groups, gender, and disease sub-types\n'

Global Uveitis treatment Market (2020 to 2026) - Featuring AbbVie, Allergan and Bausch Health Companies Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 18, 2021
Pharmaceutical, Health, Optical, Medical specialties, Clinical medicine, Uveitis, Medicine, Intermediate uveitis

The global uveitis treatment market is projected to witness considerable growth during the forecast period.

Key Points: 
  • The global uveitis treatment market is projected to witness considerable growth during the forecast period.
  • The uveitis treatment market is classified on the basis of diseases type and treatment type.
  • Based on disease type, the market is segmented into anterior uveitis, posterior uveitis, intermediate uveitis, and pan uveitis.
  • Geographically, the global uveitis treatment market is segmented into North America, Europe, Asia-Pacific, and Rest of the World.

Global Uveitis Treatment Market (2019 to 2026) - by Drug Class, Disease Type and Distribution Channel - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 29, 2020
Health, Pharmaceutical, Medical specialties, Medicine, Uveitis, Clinical medicine, Intermediate uveitis, Hypopyon

The "Uveitis Treatment Market by Drug Class, Disease Type and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2019-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Uveitis Treatment Market by Drug Class, Disease Type and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2019-2026" report has been added to ResearchAndMarkets.com's offering.
  • Different forms of drug such as cycloplegic agents, anti-inflammatory, antimicrobial drugs, immunotherapy & targeted therapies, and others are used in the treatment of uveitis.
  • The global uveitis treatment market is segmented on the basis of drug class, distribution channel, and region.
  • Disease type such as anterior uveitis, posterior uveitis, intermediate uveitis, and panuveitis are covered in the report.

Alimera Announces Regulatory Approval for ILUVIEN® in Benelux Countries for The Treatment of Non-Infectious Posterior Uveitis

Retrieved on: 
Tuesday, December 3, 2019
Medicine, Ophthalmology, Medical specialties, Uveitis, RTT, Posterior segment of eyeball, Chronic condition, Retina, Visual impairment, Intermediate uveitis

The complete Benelux approval was achieved when The Netherlands Medicines Evaluation Board informed Alimera of their approval on November 6, 2019.

Key Points: 
  • The complete Benelux approval was achieved when The Netherlands Medicines Evaluation Board informed Alimera of their approval on November 6, 2019.
  • Posterior segment non-infectious uveitis (NIPU) is a chronic, inflammatory disease affecting the posterior segment of the eye, often involving the retina, and is a leading cause of blindness in developed and developing countries.
  • In 17 European countries, ILUVIEN is indicated for the treatment of vision impairment associated with chronic DME considered insufficiently responsive to available therapies.
  • In March 2019, ILUVIEN received approval in the 17 countries under the Mutual Recognition Procedure for prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye.

Tarsius Pharma Announces Granting of Orphan Drug Designation for TRS by the European Medicines Agency

Retrieved on: 
Tuesday, November 19, 2019
Health, Articles, Medical specialties, RTT, Uveitis, Orphan drug, Glaucoma, European Medicines Agency, Intermediate uveitis

TEL AVIV,Israel, Nov. 19, 2019 /PRNewswire/ --Tarsius Pharma today announced that the European Medicines Agency (EMA), the European equivalent of the FDA, approved the designation of orphan drug for its TRS for treatment of non-infectious uveitis and has acknowledged the clinically relevant advantage for TRS in non-infectious uveitis patients with glaucoma not eligible for corticosteroid treatment.

Key Points: 
  • TEL AVIV,Israel, Nov. 19, 2019 /PRNewswire/ --Tarsius Pharma today announced that the European Medicines Agency (EMA), the European equivalent of the FDA, approved the designation of orphan drug for its TRS for treatment of non-infectious uveitis and has acknowledged the clinically relevant advantage for TRS in non-infectious uveitis patients with glaucoma not eligible for corticosteroid treatment.
  • Orphan drug designations facilitate development ofdrugs for rare diseases.
  • The TRS Platform Technology has the potential to effectively treat a broad array of autoimmune and inflammatory ocular diseases.
  • Tarsius Pharma was established in 2016and is focused on developing TRS, a breakthrough, bio-inspired platform technology for the treatment of blinding ocular diseases.

Anterior Uveitis Treatment Market Size Worth $418.23 Million By 2026: Grand View Research, Inc.

Retrieved on: 
Wednesday, September 18, 2019
Medical specialties, Medicine, Uveitis, Clinical medicine, Intermediate uveitis, Corticosteroid

SAN FRANCISCO, Sept. 18, 2019 /PRNewswire/ -- The global anterior uveitis treatment market size is expected to reach USD 418.23 million by 2026, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 5.4%.

Key Points: 
  • SAN FRANCISCO, Sept. 18, 2019 /PRNewswire/ -- The global anterior uveitis treatment market size is expected to reach USD 418.23 million by 2026, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 5.4%.
  • This disease is more common when compared to panuveitis, posterior, and intermediate uveitis.
  • Key suggestions from the report:
    Corticosteroids dominated the anterior uveitis treatment market in 2018 owing to its beneficial characteristic of minimizing inflammation in the eye.
  • Grand View Research has segmented the anterior uveitis treatment market on the basis of treatment type, distribution channel, and region:
    Anterior Uveitis Treatment Type Outlook (Revenue, USD Million, 2015 - 2026)

Anterior Uveitis Treatment Market Size Worth $418.23 Million By 2026: Grand View Research, Inc.

Retrieved on: 
Wednesday, September 18, 2019
Medical specialties, Medicine, Uveitis, Clinical medicine, Intermediate uveitis, Corticosteroid

SAN FRANCISCO, Sept. 18, 2019 /PRNewswire/ -- The global anterior uveitis treatment market size is expected to reach USD 418.23 million by 2026, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 5.4%.

Key Points: 
  • SAN FRANCISCO, Sept. 18, 2019 /PRNewswire/ -- The global anterior uveitis treatment market size is expected to reach USD 418.23 million by 2026, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 5.4%.
  • This disease is more common when compared to panuveitis, posterior, and intermediate uveitis.
  • Key suggestions from the report:
    Corticosteroids dominated the anterior uveitis treatment market in 2018 owing to its beneficial characteristic of minimizing inflammation in the eye.
  • Grand View Research has segmented the anterior uveitis treatment market on the basis of treatment type, distribution channel, and region:
    Anterior Uveitis Treatment Type Outlook (Revenue, USD Million, 2015 - 2026)